Reviewing Virpax Pharmaceuticals (NASDAQ:VRPX) & Hepion Pharmaceuticals (NASDAQ:HEPA)

Profitability

This table compares Hepion Pharmaceuticals and Virpax Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

Volatility & Risk

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.

Institutional & Insider Ownership

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Hepion Pharmaceuticals and Virpax Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93 million	($72.15)	0.00
Virpax Pharmaceuticals	N/A	N/A	-$15.19 million	($123.25)	0.00

Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Virpax Pharmaceuticals beats Hepion Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.